Background: Third-line chemotherapies for advanced breast cancer are difficult to tailor to the individual patient because of reduced tolerance and significant toxicity. Treatment with a continuous intravenous infusion of low-dose 5-fluorouracil (FU-LDCI) is generally well tolerated and thus, a reasonable option for heavily pretreated patients.
Introduction
Patients with progressive advanced breast cancer are typically in need of palliation. Depending on the type of previous adjuvant therapy, the time lag to progression, and response, or lack thereof, to an endocrine treatment, regimens containing cyclophosphamide, methotrexate, and 5-fluorouracil [1] or anthracyclines [2] are often employed. Salvage regimens include mitomycin C plus vinblastine [3] , paclitaxel [4] , docetaxel [5] and vinorelbine [6] , as well as platinum-based combinations [7] . These treatments are usually clinically effective, but their use is associated with a significant subjective and objective toxic burden.
The pyrimidine analog 5-fluorouracil (5-FU) yields a 20% response rate in patients with metastatic breast cancer when given as a single drug by bolus i.v injection [8] . The drug has a short half-life (10 minutes), and is S phase-specific [9] , making it particularly suitable for administration as a continuous infusion which enhances cell kill by increasing the exposure of dividing cells. Continuous infusion of 5-FU is very well tolerated: various studies have demonstrated that it is possible to administer doses of 1-1.4 g/m 2 /day (22.5-30 mg/ kg/day) up to 5 days, and 500 mg/m 2 /day up to 30 days [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . The limiting toxicity of 5-FU in continuous infusion is muco-cutaneous (mucositis and 'handfoot' syndrome) rather than hematological [20] . This schedule was studied especially in advanced colorectal [21] and breast cancer [10] . In the latter it was found to be particularly effective in both metastatic disease [10, 16, 18] , and in the neoadjuvant setting of large primary tumours, given in combination with other cytotoxics [22, 23] or with radiation therapy [24] .
The rationale for proposing this treatment were the expected low toxicity profile of FU-LDCI and, because of the continuity of exposure to the drug, its potential antineoplastic effect in heavily pretreated patients.
We report on the treatment results of FU-LDCI in the first 106 patients treated in our institution between 1989 and 1995, focusing also upon aspects of quality of life, patients' acceptance, and financial costs.
Patients and methods
One hundred six patients with advanced breast cancer who failed previous chemotherapy were treated by continuous infusion with low-dose 5-fluorouracil (5-FU-LDCI). All patients had progressive disease. Their median age was 56 years (range 30 to 82), and the median ECOG Performance Status was 1 (range 1 to 4). Further patient, disease and pretreatment characteristics are described in Table 1 . Ninety-four patients (89%) received 2 or more regimens of chemotherapy for advanced disease. Eighty-one percent of the patients had previously received anthracyclines, and several regimens of 5-FU were administered in 90% of the patients.
The treatment schedule (5-FU-LDCI) consisted of 5-fluorouracil 250 mg/m 2 given as an intravenous continuous infusion for 3 weeks, followed by a one-week pause. Therapy was administered on an outpatient basis through a permanent central venous device [Port-A-Cath* (Pharmacia, Diibendorf) or Chemosite* (Medarax, Zurich)) and a disposable Multiday Infusor* (Baxter, Dietlikon). In this retrospective evaluation the cumulative weekly dose was calculated from the individual flow-sheets to allow compliance and financial assessment. Dose modifications were undertaken in instances of mucous toxicity of grade 2 or worse, and consisted of interruption of the continuous infusion for one week, or until recovery. A 25% dose reduction was undertaken in subsequent courses. The patients were seen weekly by either the treating physician or an oncology nurse, at the time of disposable infusor exchange. Hematological counts were performed twice per month, while blood chemistry (liver and renal function) was assessed monthly. Assessment of response was possible for 80 patients with evaluable disease using the WHO criteria [25] . Survival was calculated from day 1 of treatment with 5-FU-LDCI. Time to progression was defined as the period from start of treatment until the date of demonstrated progressive disease based upon assessment of evaluable lesions as dictated by clinical evidence.
Subjective response and quality of life aspects were analyzed using criteria modified from Brunner [26] . For this purpose ECOG Performance Status, changes in body weight, recorded pain, overall control of other disease-related symptoms, as well as the subjective burden of treatment in terms of toxic effects and constraints, were all taken into account to define subjective response. The proportion of patients reporting an improvement of the most common symptoms of disease was also analyzed. Toxicities were recorded and evaluated according to the WHO criteria [25] .
A more formal and prospective analysis of quality of life was performed on a cohort of 13 patients who completed a short questionnaire on aspects of tolerance of therapy. This contained details about pain resulting from the implant and use of the permanent venous device, time spent visiting the hospital or clinic, constraints on physical activity, changes in normal routine as related to personal care and attire, psychological tolerance of the continuous wearing of a device, and perception of side effects of treatment.
Statistical methods
The Kaplan-Meier method [27] was used for analysis of Time to Progression (TTP) and Overall Survival (OS). Confidence intervals for response rates were calculated using the method described by Simon [28] .
Results
Eighty of the 106 patients (75%) were evaluable for objective response. Twenty-six patients were not assessed due to the lack of measurable or evaluable tumour parameters: 12 had non-measurable bone metastases, 6 had pleural effusion or ascitis, 1 patient had an inflammatory, unmeasurable breast recurrence, and 2 discontinued treatment before the second course due to intolerance of its toxic effects.
Seventeen patients had partial responses (PR: 21%, 95% CI: 14%-31%), 23 experienced stable disease (NC: 29%), and 40 (50%) had progressive disease (PD). Figure 1 shows the response rates and 95% confidence intervals by various disease and pretreatment characteristics. None of the features, including diseasefree interval, the presence of visceral disease, positive or negative estrogen receptors in the tumour, number of metastatic sites (2 or less versus more than 2), or pretreatment with 5-fluorouracil or anthracyclines, significantly predicted response rate. The median time to progression for the 41 patients who had either PR or NC was 259 days (range 82-737), and the median overall survival for the populations as a whole was 274 days (range 13-2264).
One-hundred four patients (98%) were evaluable for subjective response: 46 of them had significant subjective improvement (44%, 95% CI: 35%-54%), and 59 did not (56%). Table 2 lists the symptoms most frequently recorded as improved during therapy.
The median dose of 5-fluorouracil received was 1904 mg/week (range 753-4329). The treatment was associated with mild to moderate toxicities in a small proportion of the patients. Toxicities and complications related to the use of a permanent venous port device are listed in Figure 3 . Noteworthy are the following observations: after 3 days of therapy, one patient developed a marked hepatic cytolysis which resolved 3 days after suspension of therapy. Liver ultrasound was normal. No other known hepatotoxic therapies were administered. Liver failure was the cause of death in another patient with known non-A-non-B chronic hepatitis with cirrhosis and biopsy-proven liver metastases, whose liver test results remained twice the normal values under 5-FU treatment during the two months preceding death. After three months of treatment, a third patient suddenly developed a neurological syndrome characterized by ataxia-abasia followed by rapid deterioration and irreversible coma. The brain CT scan was negative and the clinical diagnosis was of a vertebrobasilar ischemic stroke. The patient died after two days in a coma. Five cases of relevant catheter-related complications were seen. Three patients experienced thrombosis of the subclavia vein, and a fourth of the superior cava vein. In all four the thrombosis rapidly regressed after local administration of low-dose streptokinase [29] . In an additional case a pneumothorax immediately after the positioning of the permanent venous access was observed.
Three clinical events were classified as due to cardiac toxicity of treatment. There was one episode of supraventricular tachicardia after 5 weeks of treatment, and one case of precordial pain. The two patients who experienced these symptoms were heavily pretreated with anthracyclines (more than 550 mg/m 2 ), and one had a clinically relevant reduction in cardiac function (with a left ventricular ejection fraction of 35%). The other had no history of heart disease, and all non-invasive cardiac test results were normal. She developed recurrent precordial pain upon re-challenge with the continuous infusion of low-dose 5-fluorouracil. No precordial pain recurred after cessation of treatment Thirteen patients were interviewed concerning their subjective tolerance of the treatment, which indicated that this form of therapy is generally well tolerated. The most relevant limitation described by the patients was the need for frequent visits to the clinic. 'Living with the pump' was classified as disturbing because of the restrictions it imposed on contacts with the partner, and on showering or bathing, and because it constituted a constant reminder of the disease.
Financial costs
Costs of the therapy with low-dose, continuous 5-fluorouracil, and of other single-agent treatments for metastatic breast cancer were estimated on the basis of prices in Switzerland, listed in Table 3 . The weekly cost of treatment with 5-FU using an electronic Computer- ized Ambulatory Drug Delivery (CADD) pump, which allows continuous administration of the drug for up to two weeks, was US$1,107.00. The costs of implanting a permanent intravenous access varied from US$1,137 to US$1,251, depending on the type of anesthesia (local or general) and whether or not the patient was hospitalized for this specific purpose.
Discussion
Patients with advanced breast cancer are offered several treatments, usually with the aim of palliating tumourrelated symptoms. For endocrine therapy-resistant disease prolonged treatments are typically based upon cytotoxics. Only a few patients obtain long-lasting complete remissions; the majority require new treatments once disease progresses. For many patients the use of continuous cytotoxics is associated with significant discomfort due to the subjective side effects of chemotherapy. Thus, the development of treatments which are relatively well tolerated, especially for a disease such as breast cancer which may require months and years of palliation, is a major medical challenge. One of the strategies developed to allow significant cytocidal tumour effect and at the same time better tolerance of the drugs was the use of continuous treatments. One of the first drugs applied in continuous infusions was 5-fluorouracil [14] . The frequent use of permanent venous access, the availability of a simple infusion device and the need to provide treatments with a low toxic profile in the setting of third line chemotherapy for metastatic breast cancer provided the incentive to offer this form of treatment [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Very little data is available on objective response rates in patients with advanced breast cancer treated with a third-line chemotherapy. The time-to-progression and overall survival were similar to those of other second-and third-line therapies [1] [2] [3] [4] [5] [6] [7] . It is unclear whether an objective response rate should be an endpoint of interest at all when dealing with second-and third-line treatments, or whether one should concentrate upon subjective markers of efficacy of treatment. Gregory [30] reported only a 16% response rate in unselected patients previously treated with a variety of initial regimens. Our study yielded a surprisingly large proportion of patients who had both subjective improvement (44%) and a partial response (21%). Despite the third-line therapy setting, the patients selected for the treatment in our series had better performance statuses than those described by others [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , while several common variables of advanced disease indicated a more dire prognosis.
None of the patient characteristics, seen for every type of metastatic site including bone, soft-tissues and visceral metastases, clearly predicted response ( Figure  !) • This therapy yielded only a low rate of grade 3 toxicities, with no grade 4 toxicities observed. Furthermore, the patients who were interviewed about subjective tolerance indicated a relatively high degree of satisfaction. The chosen schedule of three weeks of continuous treatment followed by a one-week pause was probably the reason for the rather low incidence of the 'handfoot syndrome' [16] . The median weekly dose received (1904 mg/wk -272 mg/day) was slightly above the dose scheduled, probably because of the low toxicity encountered during the one-week intermission. The increased dose did not seem to influence treatment outcome. Observed mucositis was slightly higher than reported by others, probably due to the increased dose. The duration of treatment was dependent almost exclusively upon tolerance, and it is noteworthy that some patients were treated for more than 2 years with no apparent problem.
Complications related to the venous port were rarely seen, and did not have permanent consequences.
We also observed several episodes of cardiac toxicity in a few patients. 5-fluorouracil is a well known cardiotoxic agent when administered in a bolus injection [31] , but it was rarely reported after protracted infusion [32] .
The continuous infusion of low-dose 5-fluorouracil was generally well accepted by the patients. As previously noted, this may be due to the low incidence of toxic effects, which was objectively demonstrated. The fact that 'living with the pump', despite difficulties, was overwhelmingly accepted by the patients is probably ascribable to the positive effect of a continuous therapy on the quality of life [33] .
The financial costs of the treatment with low-dose continuous 5-fluorouracil are slightly lower than those associated with other treatments of the same type. On the other hand, the costs of treatment with paclitaxel [4] are three-fold higher. The cost of implanting the permanent venous access were not added to those of the treatment because a permanent venous catheter had already been implanted in most of the patients to whom a third-line therapy was offered (Table 3) .
The use of a disposable elastomer infusion-pump was considered by the team of caretakers to be superior in terms of comfort for the patients. The very few times in which the use of an electronic pump was attempted, mainly in periods when the supply of the disposable pumps was insufficient, the burden of caring for the electronic device was considered an inconvenience by the patients. This issue was also briefly discussed by others [10, 11] . The disposable elastomer pumps, frequently used for non-vesicant chemotherapies and for continuous infusion of analgesics, were found to be useful, reliable, and almost always allowed administration of the prescribed dose.
In conclusion, 5-fluorouracil given at low-dose in a continuous infusion is an effective third-line palliative therapy. It is useful for patients with any type of metastatic spread, and is very well tolerated. The financial cost of the treatment is relatively low, especially as compared to the other second-and third-line treatments usually prescribed for patients with metastatic breast cancer.
